Tracers / [111In]In-PSMA-617
[111In]In-PSMA-617
Also written as [111In]In-PSMA-617; [In-111]In-PSMA-617; PSMA-617; PSMA617
- Radionuclide
- In-111 t½ 4032 min
- Modality
- SPECT
- Production route
- Cyclotron solid target
- Stage
- Research
- Syntheses indexed
- 4
What it is
- Compound class
- Small molecule (urea-based)
- Target / mechanism
- Prostate-specific membrane antigen (PSMA) PMID 37241763 / DOI 10.3390/molecules28104022
- Clinical application
- Research SPECT imaging of PSMA-positive prostate cancer; PSMA-617 is the targeting vector of the approved therapeutic [177Lu]Lu-PSMA-617 PMID 37241763 / DOI 10.3390/molecules28104022
- Theranostic pair
- <a href="/tracers/lu177-psma617/">lu177-psma617</a>
Regulatory status
- FDA
- No Drugs@FDA / openFDA drug registry — no approved application found; search: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process&searchTerm=In-111+PSMA-617
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
Precursor
- Common precursor
- DOTA-conjugated PSMA ligand PSMA-617 PMID 37241763 / DOI 10.3390/molecules28104022
- Suppliers seen in the literature
- —
- Typical final purification
- SPE
Need this precursor?We can point you to suppliers for [111In]In-PSMA-617, or handle the enquiry for you.
Get in touchQuality control Preliminary — inferred from compound class
- Ph. Eur. monograph
- —
- USP monograph
- —
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); receptor ligand with a saturable target -> molar activity (rule)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [111In]In-PSMA-617.
Get in touch